At the strategic development level of the company, in addition to establishing a platform for the development of therapeutic drugs for eye diseases and other diseases, the company also takes scientific research institutions, hospital clinical researchers, pharmaceutical companies, etc. as its main potential customers, and actively prepares to launch external service projects, including: screening and authorization of superior cell lines (cell line screening, cell line improvement and establishment of cell banks, selection of indications, differentiation of functional cells, small animal experiments); outsourcing services of experimental technologies and customized production services of cell lines; outsourcing services for the directional differentiation of induced pluripotent stem cells (iPSCs) and the preparation of organoids, as well as experiments such as drug screening, function and toxicology based on iPSC technology; and the establishment of iPS cell banks for different gene mutations or disease types.
